MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...

– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, the privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood ...

CRC screening rates in a large managed care organization were low. Among those screened, use was associated more with physicians' recommendations than with patient preferences. Multi-method study ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...

Beacon Biomedical's BeScreened-CRC blood test improves screening compliance and therefore the probability of survival while dramatically reducing the cost of treatment of CRC without the need for ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...

Please provide your email address to receive an email when new articles are posted on . Geneoscopy Inc. announced favorable results from its CRC-PREVENT trial, which assessed noninvasive, stool-based, ...